IMAX global box office receipts to drive Q3 upside: analysts

Wedbush analysts reiterated an 'Outperform' rating and $39 price target for IMAX Corp, projecting the company to surpass peak EBITDA margins within two years. This optimism is driven by a 'trifecta' of factors including an uptick in filmed-for-IMAX titles, expanding global footprint, and diversified content, solidifying IMAX's role as a critical partner for major theatrical releases. Shares rose 1.7% following the report, ahead of the company's Q3 2025 earnings release.

Analysis

Wedbush analysts have reiterated an 'Outperform' rating for IMAX Corp (NYSE:IMAX) with a $39 price target, projecting the company to exceed peak EBITDA margins within the next two years. This positive outlook, driven by a "trifecta" of growth factors, led to a 1.7% increase in IMAX shares to approximately $32 in Friday's late-morning trading.

The analysts highlight four key drivers underpinning this optimism: a significant uptick in the volume and quality of filmed-for-IMAX (FFI) titles expected in Q4 and 2026, which should lead to incremental market share gains. Further revenue boosts are anticipated from a diversified global box office mix of local language and international fare, increased alternative content offerings, and continued global footprint expansion.

These factors collectively underscore IMAX's strengthening position as an essential partner for major theatrical releases across various genres, languages, and geographies, as evidenced by its robust 2025-2026 global film lineup. The company's strategic prominence in Hollywood and worldwide is seen as a key differentiator ahead of its Q3 2025 financial results on October 23.

Key Decisions for Investors

• Investors should consider the reiterated 'Outperform' rating and $39 price target from Wedbush as a strong signal of potential upside, supported by identified growth drivers.
• Monitor IMAX's Q3 2025 earnings report on October 23 for confirmation of operational strength and alignment with analyst projections for EBITDA margin expansion.
• Evaluate the company's execution on its "trifecta" strategy, particularly the pipeline of FFI titles and global expansion, as key indicators for sustained market share gains and revenue growth.